The Top 10 Hidden Champions in Digital Oncology Market on R2GConnect
The digital oncology market leverages cutting-edge technologies for drug development, diagnostics, clinical decision support, remote monitoring, and self-management. R2GConnect highlights the hidden champions within this segment from its extensive database of over 8,300 digital health companies. Discover the Top 10 and connect on the R2GConnect platform.
The digital oncology market is transforming cancer care by integrating advanced technologies into all facets of treatment and management. By utilizing AI and data analytics, oncology solutions offer personalized treatment plans, enable early detection, and improve patient monitoring. As a result, investors and partners have been increasing their initiatives together with the digital oncology market players to drive continuous improvement of cancer care practices.
Thyme Care, a value-based cancer care enabler, closed $95 million USD funding round in June 2024 with investors like Concord Health Partners and CVS Health, following its series B round of $60 million USD in less than a year ago.
Personalized support, monitoring, coaching, and self-management solution providers for cancer patients have also been on the rise with their recent partnership announcements. For example, Osara Health collaborated with Guardian Life Insurance Company of America, to offer its 12-week Cancer Coach program including education modules and health coaching for mental health and wellness of members diagnosed with cancer. Elekta announced its partnership with Merck & Co. (MSD) to develop digital patient monitoring via its Kaiku Health solution for advanced renal cell carcinoma patients.
Mika Health signed an agreement with two pharma giants, AstraZeneca and Daiichi Sankyo, through UNITE program, to enhance support for breast cancer patients in Switzerland by offering mental health coaching, AI-powered recommendations, and symptom monitoring through its app.
In a strategic move, Sidekick Health recently acquired PINK!, owner of the DiGA listed PINK Coach app for breast cancer patients.
Additionally, AI-powered solution providers are also making a significant impact in personalizing cancer treatment pathways, early diagnosis, and clinical decision support. ArteraAI, with its multi-modal artificial intelligence-backed prognostic prostate cancer solution, raised $20 million USD in early 2024. Lunit, a South Korean AI cancer diagnostics solutions provider expanding its footprint in North America and Europe, also announced $150 million USD funding in 2024. Qure.ai, known for its AI-augmented detection of tuberculosis, lung cancer, and stroke from imaging data, received a strategic investment from Merck Global Health Innovation Fund in June 2024.
While the front-runners of the digital oncology market have long been under the radar of partners and investors, the “hidden champions” are as well making significant strides and contributing to the further growth of this market segment.
R2GConnect, hosting over 8,300 companies globally as a digital health partnership builder platform, shares another curated watchlist featuring the Top 10 hidden champions in the digital oncology market.
Driven by AI-powered analysis of R2GConnect’s extensive database on the member companies, the Top10 hidden champions are selected based on their services and performance across key metrics including Dynamism, Readiness to Execute, and Aspiration.
Dynamism assesses the ongoing growth of the companies since their inception, by taking the financial sturdiness of their business into account, highlighting their sustainability as a stand-alone business. Companies like Quibim, Huna, Genomate Health, and Turbine stand out with their robustness and continuous growth.
Readiness to Execute evaluates a company’s readiness in scaling-up, with comprehensive business and distribution models, experience and size of its team, and its awareness of the competitive market landscape. Fimo Health, Saventic Health, and SymBioSys are some of the companies having strong competence in planning and executing business strategies to stand out in the competitive digital oncology segment.
Lastly, Aspiration takes a look at the value proposition and implementation of emerging technologies and AI, available patents, pilot and clinical studies, and the addressable market sizes. Mobio Interactive and SymBioSys show higher aspiration results, while others have room for improvement in clinical studies and patents.
As the digital oncology market grows stronger and becomes competitive with a range of solution providers, the Top 10 hidden champions presented by R2Gconnect offer a fresh perspective to the stakeholders looking out for partnerships and investments in this market segment.
To find out which company best suits your requirements, summarize what you are looking for in a briefing (open call) on R2Gconnect, and tap into the digital oncology solution providers that best fit to your request. Search for the best partners in our growing startup Radar database (8,300+ startups). Find your hidden champion.
Get started and create your first briefing at www.R2GConnect.com or book a demo session at https://www.r2gconnect.com/r2g-demo-booking
